Trials / Completed
CompletedNCT03728023
A Study of AZD4205 in Healthy Adult Subjects
A Phase I, Randomized, Double Blind, Placebo Controlled 2-Parts Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD4205 Following Single and Multiple Ascending Dose in Healthy Adult Subjects, and to Assess the Effect of Food on the Pharmacokinetics of AZD4205
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Dizal Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is to assess the safety, tolerability, pharmacokinetics of AZD4205 following single and multiple ascending dose in healthy adult subjects, and to assess the effect of food on the pharmacokinetics of AZD4205.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD4205 | SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days |
| DRUG | Placebo | Single dose in SAD and once daily for 14 days |
Timeline
- Start date
- 2018-11-12
- Primary completion
- 2019-08-20
- Completion
- 2019-08-20
- First posted
- 2018-11-01
- Last updated
- 2020-08-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03728023. Inclusion in this directory is not an endorsement.